Please login to the form below
olaratumab
This page shows the latest olaratumab news and features for those working in and with pharma, biotech and healthcare.
Lilly bags EU approval for cancer treatment Lartruvo
Dr Sue Mahony, president of Lilly Oncology, said: “ With this decision, olaratumab is now authorised for use in the EU, offering a new treatment option for soft tissue sarcoma patients in
Latest news
-
Lilly snags first approval for sarcoma drug Lartruvo
The US FDA granted accelerated approval to Lartruvo (olaratumab) used in combination with doxorubicin chemotherapy in STS patients who cannot be cured using surgery or radiotherapy, and who have a form
-
Lilly closes on first approval for sarcoma drug Lartruvo
The EMA panel gave a green light to a conditional approval of Lartruvo (olaratumab), used in combination with doxorubicin chemotherapy, for advanced STS patients who cannot be treated with surgery or ... Olaratumab is also under regulatory review in the
-
Lilly planning 20 new launches by 2023
Top projects include PDGF inhibitor olaratumab, which was granted priority review by the FDA earlier this month for soft tissue sarcoma, and CDK4/6 inhibitor abemaciclib for advanced breast cancer and ... Olaratumab will see its first marketing
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Sudler London - Account Director
-
Competitive
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Systematic Review Lead- London
-
Negotiable
-
Associate Scientific Director
-
Salary TBC
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Sudler London - Senior Medical Writer
-
Competitive
-
Account Manager
-
Negotiable
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Senior Writer, Healthcare Advertising, London
-
Excellent package
Subscribe to our email news alerts
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
